{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.3"},{"groupId":"OG001","value":"1.3"},{"groupId":"OG002","value":"1.3"}]}],"title":"Statement a): Strongly Disagree"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.6"},{"groupId":"OG001","value":"1.3"},{"groupId":"OG002","value":"0.0"}]}],"title":"Statement a): Disagree"},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.5"},{"groupId":"OG001","value":"8.8"},{"groupId":"OG002","value":"6.3"}]}],"title":"Statement a): Neutral"},{"categories":[{"measurements":[{"groupId":"OG000","value":"28.8"},{"groupId":"OG001","value":"28.8"},{"groupId":"OG002","value":"28.8"}]}],"title":"Statement a): Agree"},{"categories":[{"measurements":[{"groupId":"OG000","value":"50.6"},{"groupId":"OG001","value":"52.5"},{"groupId":"OG002","value":"48.8"}]}],"title":"Statement a): Strongly Agree"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.5"},{"groupId":"OG001","value":"3.8"},{"groupId":"OG002","value":"1.3"}]}],"title":"Statement a): Not Applicable"},{"categories":[{"measurements":[{"groupId":"OG000","value":"8.8"},{"groupId":"OG001","value":"3.8"},{"groupId":"OG002","value":"13.8"}]}],"title":"Statement a): Answer Missing"},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.6"},{"groupId":"OG001","value":"8.8"},{"groupId":"OG002","value":"2.5"}]}],"title":"Statement b): Strongly Disagree"},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.8"},{"groupId":"OG001","value":"3.8"},{"groupId":"OG002","value":"3.8"}]}],"title":"Statement b): Disagree"},{"categories":[{"measurements":[{"groupId":"OG000","value":"14.4"},{"groupId":"OG001","value":"16.3"},{"groupId":"OG002","value":"12.5"}]}],"title":"Statement b): Neutral"},{"categories":[{"measurements":[{"groupId":"OG000","value":"18.1"},{"groupId":"OG001","value":"17.5"},{"groupId":"OG002","value":"18.8"}]}],"title":"Statement b): Agree"},{"categories":[{"measurements":[{"groupId":"OG000","value":"46.3"},{"groupId":"OG001","value":"46.3"},{"groupId":"OG002","value":"46.3"}]}],"title":"Statement b): Strongly Agree"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.5"},{"groupId":"OG001","value":"2.5"},{"groupId":"OG002","value":"2.5"}]}],"title":"Statement b): Not Applicable"},{"categories":[{"measurements":[{"groupId":"OG000","value":"9.4"},{"groupId":"OG001","value":"5.0"},{"groupId":"OG002","value":"13.8"}]}],"title":"Statement b): Answer Missing"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.6"},{"groupId":"OG001","value":"0.0"},{"groupId":"OG002","value":"1.3"}]}],"title":"Statement c): Strongly Disagree"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.6"},{"groupId":"OG001","value":"0.0"},{"groupId":"OG002","value":"1.3"}]}],"title":"Statement c): Disagree"},{"categories":[{"measurements":[{"groupId":"OG000","value":"13.1"},{"groupId":"OG001","value":"15.0"},{"groupId":"OG002","value":"11.3"}]}],"title":"Statement c): Neutral"},{"categories":[{"measurements":[{"groupId":"OG000","value":"26.3"},{"groupId":"OG001","value":"28.8"},{"groupId":"OG002","value":"23.8"}]}],"title":"Statement c): Agree"},{"categories":[{"measurements":[{"groupId":"OG000","value":"48.8"},{"groupId":"OG001","value":"50.0"},{"groupId":"OG002","value":"47.5"}]}],"title":"Statement c): Strongly Agree"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.3"},{"groupId":"OG001","value":"1.3"},{"groupId":"OG002","value":"1.3"}]}],"title":"Statement c): Not Applicable"},{"categories":[{"measurements":[{"groupId":"OG000","value":"9.4"},{"groupId":"OG001","value":"5.0"},{"groupId":"OG002","value":"13.8"}]}],"title":"Statement c): Answer Missing"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.3"},{"groupId":"OG001","value":"1.3"},{"groupId":"OG002","value":"1.3"}]}],"title":"Statement d): Strongly Disagree"},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.8"},{"groupId":"OG001","value":"1.3"},{"groupId":"OG002","value":"6.3"}]}],"title":"Statement d): Disagree"},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.6"},{"groupId":"OG001","value":"5.0"},{"groupId":"OG002","value":"6.3"}]}],"title":"Statement d): Neutral"},{"categories":[{"measurements":[{"groupId":"OG000","value":"23.1"},{"groupId":"OG001","value":"26.3"},{"groupId":"OG002","value":"20.0"}]}],"title":"Statement d): Agree"},{"categories":[{"measurements":[{"groupId":"OG000","value":"56.3"},{"groupId":"OG001","value":"60.0"},{"groupId":"OG002","value":"52.5"}]}],"title":"Statement d): Strongly Agree"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.3"},{"groupId":"OG001","value":"1.3"},{"groupId":"OG002","value":"1.3"}]}],"title":"Statement d): Not Applicable"},{"categories":[{"measurements":[{"groupId":"OG000","value":"8.8"},{"groupId":"OG001","value":"5.0"},{"groupId":"OG002","value":"12.5"}]}],"title":"Statement d): Answer Missing"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.3"},{"groupId":"OG001","value":"1.3"},{"groupId":"OG002","value":"1.3"}]}],"title":"Statement e): Strongly Disagree"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.9"},{"groupId":"OG001","value":"1.3"},{"groupId":"OG002","value":"2.5"}]}],"title":"Statement e): Disagree"},{"categories":[{"measurements":[{"groupId":"OG000","value":"8.8"},{"groupId":"OG001","value":"11.3"},{"groupId":"OG002","value":"6.3"}]}],"title":"Statement e): Neutral"},{"categories":[{"measurements":[{"groupId":"OG000","value":"21.9"},{"groupId":"OG001","value":"21.3"},{"groupId":"OG002","value":"22.5"}]}],"title":"Statement e): Agree"},{"categories":[{"measurements":[{"groupId":"OG000","value":"55.0"},{"groupId":"OG001","value":"58.8"},{"groupId":"OG002","value":"51.3"}]}],"title":"Statement e): Strongly Agree"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.9"},{"groupId":"OG001","value":"1.3"},{"groupId":"OG002","value":"2.5"}]}],"title":"Statement e): Not Applicable"},{"categories":[{"measurements":[{"groupId":"OG000","value":"9.4"},{"groupId":"OG001","value":"5.0"},{"groupId":"OG002","value":"13.8"}]}],"title":"Statement e): Answer Missing"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.6"},{"groupId":"OG001","value":"0.0"},{"groupId":"OG002","value":"1.3"}]}],"title":"Statement f): Strongly Disagree"},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.4"},{"groupId":"OG001","value":"3.8"},{"groupId":"OG002","value":"5.0"}]}],"title":"Statement f): Disagree"},{"categories":[{"measurements":[{"groupId":"OG000","value":"11.9"},{"groupId":"OG001","value":"16.3"},{"groupId":"OG002","value":"7.5"}]}],"title":"Statement f): Neutral"},{"categories":[{"measurements":[{"groupId":"OG000","value":"24.4"},{"groupId":"OG001","value":"20.0"},{"groupId":"OG002","value":"28.8"}]}],"title":"Statement f): Agree"},{"categories":[{"measurements":[{"groupId":"OG000","value":"48.1"},{"groupId":"OG001","value":"53.8"},{"groupId":"OG002","value":"42.5"}]}],"title":"Statement f): Strongly Agree"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.3"},{"groupId":"OG001","value":"1.3"},{"groupId":"OG002","value":"1.3"}]}],"title":"Statement f): Not Applicable"},{"categories":[{"measurements":[{"groupId":"OG000","value":"9.4"},{"groupId":"OG001","value":"5.0"},{"groupId":"OG002","value":"13.8"}]}],"title":"Statement f): Answer Missing"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.6"},{"groupId":"OG001","value":"0.0"},{"groupId":"OG002","value":"1.3"}]}],"title":"Statement g): Strongly Disagree"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0"},{"groupId":"OG001","value":"0.0"},{"groupId":"OG002","value":"0.0"}]}],"title":"Statement g): Disagree"},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.9"},{"groupId":"OG001","value":"8.8"},{"groupId":"OG002","value":"5.0"}]}],"title":"Statement g): Neutral"},{"categories":[{"measurements":[{"groupId":"OG000","value":"31.3"},{"groupId":"OG001","value":"30.0"},{"groupId":"OG002","value":"32.5"}]}],"title":"Statement g): Agree"},{"categories":[{"measurements":[{"groupId":"OG000","value":"48.8"},{"groupId":"OG001","value":"52.5"},{"groupId":"OG002","value":"45.0"}]}],"title":"Statement g): Strongly Agree"},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.1"},{"groupId":"OG001","value":"3.8"},{"groupId":"OG002","value":"2.5"}]}],"title":"Statement g): Not Applicable"},{"categories":[{"measurements":[{"groupId":"OG000","value":"9.4"},{"groupId":"OG001","value":"5.0"},{"groupId":"OG002","value":"13.8"}]}],"title":"Statement g): Answer Missing"}],"denoms":[{"counts":[{"groupId":"OG000","value":"160"},{"groupId":"OG001","value":"80"},{"groupId":"OG002","value":"80"}],"units":"Participants"}],"description":"Healthcare professionals (HCPs) who prepared study treatment within the pharmacy/drug preparation area responded at Cycle 6 of the Treatment Cross-Over Period to the following HCPQ-Drug Preparation Room Question 2: \"If all P+H IV infusions are switched to FDC SC injections, please indicate how strongly you agree or disagree with each of the following statements: a) Staff will have increased availability for other tasks in the pharmacy; b) Administrative procedures around FDC SC will require less time; c) FDC SC formulations will provide more flexibility for staff in managing their workload; d) Due to ready-to-use FDC SC formulations, potential dosing errors will be avoided; e) Due to ready-to-use FDC SC formulations, there will be less drug wastage; f) Without having to reconstitute the drug, less storage space for FDC SC related supplies will be required in the pharmacy; g) Preparation procedures and associated time staff time commitment will be reduced.\"","groups":[{"description":"This analysis set includes all healthcare professionals who treated participants from Arms A and B and completed the HCPQ questionnaire, which was administered at the last treatment cycle in the Treatment Cross-Over Period of the study. During the Treatment Cross-Over Period of the study, all participants received their first 6 cycles of treatment in accordance with the study arm to which they were randomized: Arm A) pertuzumab IV and trastuzumab IV (P+H IV) for 3 treatment cycles followed by the pertuzumab and trastuzumab fixed-dose combination for subcutaneous administration (PH FDC SC) for 3 treatment cycles (1 cycle = 21 days); or Arm B) PH FDC SC for 3 treatment cycles followed by P+H IV for 3 treatment cycles (1 cycle = 21 days). Following completion of this study period, participants chose one of the two study treatments to receive in the Treatment Continuation Period for the remaining anti-HER2 treatment cycles (18 planned cycles in total, including pre-study neoadjuvant treatment). After completing study treatment, participants entered the Follow-up Period wherein they were to be followed for 3 years from the date the last participant was randomized.","id":"OG000","title":"All Healthcare Professionals"},{"description":"In the Treatment Cross-Over Period of the study, participants randomized to Arm A first received pertuzumab IV and trastuzumab IV (P+H IV) administration for 3 treatment cycles followed by the pertuzumab and trastuzumab fixed-dose combination for subcutaneous administration (PH FDC SC) for 3 treatment cycles (1 cycle = 21 days). Following completion of this study period, participants chose one of the two study treatments to receive in the Treatment Continuation Period for the remaining anti-HER2 treatment cycles (18 planned cycles in total, including pre-study neoadjuvant treatment). After completing study treatment, participants entered the Follow-up Period wherein they were to be followed for 3 years from the date the last participant was randomized.","id":"OG001","title":"A: P+H IV Followed by PH FDC SC"},{"description":"In the Treatment Cross-Over Period of the study, participants randomized to Arm B first received the pertuzumab and trastuzumab fixed-dose combination for subcutaneous administration (PH FDC SC) for 3 treatment cycles followed by pertuzumab intravenous (IV) and trastuzumab IV (P+H IV) administration for 3 treatment cycles (1 cycle = 21 days). Following completion of this study period, participants chose one of the two study treatments to receive in the Treatment Continuation Period for the remaining anti-HER2 treatment cycles (18 planned cycles in total, including pre-study neoadjuvant treatment). After completing study treatment, participants entered the Follow-up Period wherein they were to be followed for 3 years from the date the last participant was randomized.","id":"OG002","title":"B: PH FDC SC Followed by P+H IV"}],"paramType":"NUMBER","populationDescription":"The number analyzed includes healthcare professionals (HCPs) who completed any part of the survey at treatment Cycle 6.","reportingStatus":"POSTED","timeFrame":"Day 1 of Cycle 6 (each cycle is 21 days)","title":"Percentage of Healthcare Professionals (HCPs) by Their Responses on Perception of Impact of PH FDC SC on Clinical Management and Clinical Efficiency, Question 2 of the HCPQ - Drug Preparation Room","type":"SECONDARY","unitOfMeasure":"Percentage of HCPs"}